Changes

81. SongTao Q, et al., (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269–273, PMID 22034964.  

81. SongTao Q, et al., (2012). IDH mutations predict longer survival and response to temozolomide in secondary glioblastoma. Cancer Sci 103:269–273, PMID 22034964.  

82. Molenaar, R. J. et al. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors. Clin. Cancer Res. 24, 1705–1715 (2018). PMID: 29339439  

82. Molenaar RJ, et al., (2018). IDH1/2 mutations sensitize acute myeloid leukemia to PARP inhibition and this is reversed by IDH1/2-mutant inhibitors. Clin Cancer Res 24:1705–1715, PMID 29339439.

83. Lu, Y. et al. Chemosensitivity of IDH1-Mutated Gliomas Due to an Impairment in PARP1-Mediated DNA Repair. Cancer Res. 77, 1709–1718 (2017). PMID: 28202508  

83. Lu Y, et al., (2017). Chemosensitivity of IDH1-mutated gliomas due to an impairment in PARP1-mediated DNA repair. Cancer Res 77:1709–1718, PMID 28202508.

84. Popovici-Muller, J. et al. Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med. Chem. Lett. 3, 850–855 (2012). PMID: 24900389  

84. Popovici-Muller J, et al., (2012). Discovery of the first potent inhibitors of mutant IDH1 that lower tumor 2-HG in vivo. ACS Med Chem Lett 3:850–855, PMID 24900389.

85. Popovici-Muller, J. et al. Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers. ACS Med. Chem. Lett. 9, 300–305 (2018). PMID: 29670690  

85. Popovici-Muller J, et al., (2018). Discovery of AG-120 (ivosidenib): a first-in-class mutant IDH1 inhibitor for the treatment of IDH1 mutant cancers. ACS Med Chem Lett 9:300–305, PMID 29670690.

86. Rohle, D. et al. An Inhibitor of Mutant IDH1 Delays Growth and Promotes Differentiation of Glioma Cells. Science 340, 626–630 (2013). PMID: 23558169  

86. Rohle D, et al., (2013). An inhibitor of mutant IDH1 delays growth and promotes differentiation of glioma cells. Science 340:626–630, PMID 23558169.

87. Li, L. et al. Treatment with a Small Molecule Mutant IDH1 Inhibitor Suppresses Tumorigenic Activity and Decreases Production of the Oncometabolite 2-Hydroxyglutarate in Human Chondrosarcoma Cells. PLOS ONE 10, e0133813 (2015). PMID: 26368816  

87. Li L, et al., (2015). Treatment with a small molecule mutant IDH1 inhibitor suppresses tumorigenic activity and decreases production of the oncometabolite 2-Hydroxyglutarate in human chondrosarcoma cells. PLOS ONE 10:e0133813, PMID 26368816.

88. Birendra, K. C. & DiNardo, C. D. Evidence for Clinical Differentiation and Differentiation Syndrome in Patients With Acute Myeloid Leukemia and IDH1 Mutations Treated With the Targeted Mutant IDH1 Inhibitor, AG-120. Clin. Lymphoma Myeloma Leuk. 16, 460–465 (2016). PMID: 27245312

88. Birendra KC and DiNardo CD, (2016). Evidence for clinical differentiation and differentiation syndrome in patients with acute myeloid leukemia and IDH1 mutations treated with the targeted mutant IDH1 inhibitor, AG-120. Clin Lymphoma Myeloma Leuk 16:460–465, PMID 27245312.

== Notes ==

== Notes ==